D. Ilson

发表

Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma.

S. Groshen, P. Laird, D. Beer, 2000, Journal of the National Cancer Institute.

Chemotherapy and combined-modality therapy for esophageal cancer.

D. Kelsen, D. Ilson, D. Ilson, 1995, Chest.

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face

G. Schwartz, E. Casper, D. Kelsen, 1999, Cancer.

Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.

W. Enker, N. Kemeny, J. Guillem, 1997, International journal of radiation oncology, biology, physics.

Irinotecan and cisplatin in upper gastrointestinal malignancies.

L. Saltz, P. Enzinger, D. Kelsen, 1998, Oncology.

Preoperative 5‐fluorouracil, low‐dose leucovorin, and concurrent radiation therapy for rectal cancer

W. Enker, N. Kemeny, J. Guillem, 1994, Cancer.

Chemotherapy in esophageal cancer.

P. Enzinger, D. Kelsen, D. Ilson, 1999, Seminars in oncology.

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

P. Maslak, J. Werner, G. Schwartz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.

J. Ajani, D. Kelsen, D. Ilson, 1996, Seminars in oncology.

Phase II trial of paclitaxel in patients with soft-tissue sarcoma.

G. Schwartz, J. Bertino, E. Casper, 1998, Cancer Investigation.

Paclitaxel in the treatment of carcinoma of the esophagus.

J. Ajani, D. Kelsen, D. Ilson, 1995, Seminars in oncology.

A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report.

J. Ajani, R. Pazdur, D. Kelsen, 1994, Seminars in oncology.

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

N. Kemeny, L. Saltz, D. Kelsen, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

N. Kemeny, G. Schwartz, L. Saltz, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

N. Kemeny, G. Schwartz, L. Saltz, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.

J. Ajani, R. Pazdur, P. Lynch, 1994, Journal of the National Cancer Institute.

A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report.

M. Bains, R. Ginsberg, D. Kelsen, 1997, Seminars in oncology.

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, R. Mayer, 2022, ESMO open.

134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocar

P. Enzinger, D. Ilson, J. Huang, 2023, Annals of Oncology.